561 related articles for article (PubMed ID: 37474112)
1. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chiang FT; Tu YK
Eur J Endocrinol; 2023 Jul; 189(1):S17-S25. PubMed ID: 37474112
[TBL] [Abstract][Full Text] [Related]
2. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
Lin DS; Lee JK; Hung CS; Chen WJ
Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
[TBL] [Abstract][Full Text] [Related]
4. Restricted Mean Survival Time Analysis to Estimate SGLT2i-Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan.
Peng ZY; Yang CT; Kuo S; Wu CH; Lin WH; Ou HT
JAMA Netw Open; 2022 Dec; 5(12):e2246928. PubMed ID: 36520437
[TBL] [Abstract][Full Text] [Related]
5. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.
Kaze AD; Zhuo M; Kim SC; Patorno E; Paik JM
Cardiovasc Diabetol; 2022 Mar; 21(1):47. PubMed ID: 35321742
[TBL] [Abstract][Full Text] [Related]
6. Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Patel SM; Kang YM; Im K; Neuen BL; Anker SD; Bhatt DL; Butler J; Cherney DZI; Claggett BL; Fletcher RA; Herrington WG; Inzucchi SE; Jardine MJ; Mahaffey KW; McGuire DK; McMurray JJV; Neal B; Packer M; Perkovic V; Solomon SD; Staplin N; Vaduganathan M; Wanner C; Wheeler DC; Zannad F; Zhao Y; Heerspink HJL; Sabatine MS; Wiviott SD
Circulation; 2024 Jun; 149(23):1789-1801. PubMed ID: 38583093
[TBL] [Abstract][Full Text] [Related]
7. Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis.
Li X; Wu H; Peng H; Jiang H
Front Endocrinol (Lausanne); 2022; 13():1078686. PubMed ID: 36589800
[TBL] [Abstract][Full Text] [Related]
8. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
Am Heart J; 2021 Feb; 232():10-22. PubMed ID: 33214130
[TBL] [Abstract][Full Text] [Related]
9. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
[TBL] [Abstract][Full Text] [Related]
10. Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.
Sabouret P; Bocchino PP; Angelini F; D'Ascenzo F; Galati G; Fysekidis M; DE Ferrari GM; Fischman DL; Bhatt DL; Biondi-Zoccai G
Minerva Cardiol Angiol; 2023 Apr; 71(2):199-207. PubMed ID: 35195376
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Zhao Z; Jin P; Zhang Y; Hu X; Tian C; Liu D
Front Cardiovasc Med; 2022; 9():826684. PubMed ID: 35557542
[TBL] [Abstract][Full Text] [Related]
12. Sodium-glucose Cotransporter-2 Inhibitors in Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with Type 2 Diabetes Mellitus: A Meta-analysis.
Kovil R; Chawla M; Shah T; Sahoo A; Makkar B; Kesavadev J; Seshadri K; Tiwaskar M; Rajput R; Phatak S; Majumdar S; Gupta S
J Assoc Physicians India; 2022 Aug; 70(8):11-12. PubMed ID: 36082726
[TBL] [Abstract][Full Text] [Related]
13. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
McGuire DK; Shih WJ; Cosentino F; Charbonnel B; Cherney DZI; Dagogo-Jack S; Pratley R; Greenberg M; Wang S; Huyck S; Gantz I; Terra SG; Masiukiewicz U; Cannon CP
JAMA Cardiol; 2021 Feb; 6(2):148-158. PubMed ID: 33031522
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
[TBL] [Abstract][Full Text] [Related]
16. Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis.
Diallo A; Carlos-Bolumbu M; Galtier F
Acta Diabetol; 2023 Dec; 60(12):1651-1662. PubMed ID: 37439858
[TBL] [Abstract][Full Text] [Related]
17. Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
Banerjee M; Maisnam I; Pal R; Mukhopadhyay S
Eur Heart J; 2023 Oct; 44(37):3686-3696. PubMed ID: 37605637
[TBL] [Abstract][Full Text] [Related]
18. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.
Zhang Y; Jiang L; Wang J; Wang T; Chien C; Huang W; Fu X; Xiao Y; Fu Q; Wang S; Zhao J
Cardiovasc Diabetol; 2022 Nov; 21(1):232. PubMed ID: 36335326
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Outcomes With Empagliflozin and Dapagliflozin in Patients Without Diabetes.
Singh S; Garg A; Tantry US; Bliden K; Gurbel PA; Gulati M
Am J Cardiol; 2024 May; 218():24-31. PubMed ID: 38432338
[TBL] [Abstract][Full Text] [Related]
20. Roles for SGLT2 Inhibitors in Cardiorenal Disease.
Green JB; McCullough PA
Cardiorenal Med; 2022; 12(3):81-93. PubMed ID: 35835083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
